Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Endocrine Research|March 22, 2025
Management of Diabetes in Patients with Chronic Kidney DiseaseJayachidambaram Ambalavanan, Maria Luiza Caramori
International Journal of Molecular Sciences|January 28, 2026
Inflammation and Diabetic Kidney DiseaseRong Mei Zhang, Maria Luiza Caramori
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 4, 2014
Glomerular structural-functional relationship models of diabetic nephropathy are robust in type 1 diabetic patientsMichael Mauer, Maria Luiza Caramori, Paola Fioretto, et al.
Diabetes|November 25, 2003
The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetesMaria Luiza Caramori, Luis Henrique Canani, Luciana A Costa, et al.
Diabetes Care|May 13, 2011
Microalbuminuria in patients with cystic fibrosisMelanie Lind-Ayres, William Thomas, Bonnie Holme, et al.
Kidney International|October 8, 2025
Heterogeneity in the relationships between albuminuria and glomerular structure in type 1 and type 2 diabetesBehzad Najafian, Maria Luiza Caramori, Michele Dalla Vestra, et al.
Diabetes Care|December 24, 2004
Diabetic nephropathy: diagnosis, prevention, and treatmentJorge L Gross, Mirela J de Azevedo, Sandra P Silveiro, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 1, 2006
Cellular basis of diabetic nephropathy: IV. Antioxidant enzyme mRNA expression levels in skin fibroblasts of type 1 diabetic sibling pairsMaria Luiza Caramori, Youngki Kim, Paola Fioretto, et al.
Diabetes, Obesity & Metabolism|October 4, 2022
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist usePeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.
Kidney International Reports|June 15, 2026
Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension StatusRicardo Correa-Rotter, Peter Rossing, Maria Eugenia Canziani, et al.
Pageof 2